Company profile for Oak Hill Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Oak Hill Bio is a company focused on clinical-stage neonatology and rare disease therapeutics, dedicated to crafting transformative medications for highly premature infants and individuals grappling with rare autoimmune disorders. Established to progress a portfolio of promising investigational therapeutics, both in clinical and preclinical stages, Oak Hill strives to introduce innovation to a drug development arena that has e...
Oak Hill Bio is a company focused on clinical-stage neonatology and rare disease therapeutics, dedicated to crafting transformative medications for highly premature infants and individuals grappling with rare autoimmune disorders. Established to progress a portfolio of promising investigational therapeutics, both in clinical and preclinical stages, Oak Hill strives to introduce innovation to a drug development arena that has experienced limited advancements in the past two decades. Our team brings together a wealth of knowledge in rare diseases and neonatology.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
Altrincham, Cheshire
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Clinical Outsourcing

Clinical Outsourcing

Not Confirmed

envelop Contact Supplier

Clinical Outsourcing

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20250909625038/en/Oak-Hill-Bio-Spotlights-Publication-Detailing-Discovery-and-Initial-Development-of-Rugonersen-in-Nucleic-Acids-Research

BUSINESSWIRE
09 Sep 2025

https://www.businesswire.com/news/home/20250711178170/en/Oak-Hill-Bio-Announces-Publication-of-Rugonersen-Phase-1-Study-Results-in-Nature-Medicine

BUSINESSWIRE
11 Jul 2025

https://www.businesswire.com/news/home/20250415795863/en/Oak-Hill-Bio-Enters-into-Exclusive-License-Agreement-with-Roche-to-Obtain-Global-Rights-for-a-Phase-3-Ready-Potential-Best-in-Class-Treatment-for-Individuals-with-Angelman-Syndrome

BUSINESSWIRE
15 Apr 2025

https://www.businesswire.com/news/home/20241007586328/en

BUSINESSWIRE
07 Oct 2024

https://www.prnewswire.com/news-releases/oak-hill-bio-and-chiesi-group-announce-first-patient-enrolled-in-the-resumed-phase-2b-clinical-study-evaluating-ohb-607-for-the-prevention-of-bronchopulmonary-dysplasia-the-most-common-cause-of-chronic-lung-disease-in-premature-i-302148908.html

PR NEWSWIRE
17 May 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty